1 INTRODUCTION 27
1.1 STUDY OBJECTIVES 27
1.2 MARKET DEFINITION 27
1.2.1 INCLUSIONS AND EXCLUSIONS 28
TABLE 1 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: INCLUSIONS AND EXCLUSIONS 28
1.3 MARKET SCOPE 28
FIGURE 1 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET SEGMENTATION 28
1.3.1 REGIONS COVERED 28
1.3.2 YEARS CONSIDERED 29
1.4 CURRENCY CONSIDERED 29
1.5 UNITS CONSIDERED 29
1.6 LIMITATIONS 29
1.7 STAKEHOLDERS 30
1.7.1 IMPACT OF RECESSION 30
2 RESEARCH METHODOLOGY 31
2.1 RESEARCH DATA 31
FIGURE 2 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: RESEARCH DESIGN 31
2.1.1 SECONDARY DATA 32
2.1.1.1 Key data from secondary sources 32
2.1.2 PRIMARY DATA 33
2.1.2.1 Key data from primary sources 33
2.1.2.2 Companies participating in primary research 33
2.1.2.3 Breakdown of primary interviews 34
2.2 DEMAND-SIDE APPROACH 34
FIGURE 3 MAIN MATRIX CONSIDERED TO CONSTRUCT AND ASSESS DEMAND FOR PHARMACEUTICAL GRADE LITHIUM CARBONATE 34
2.3 MARKET SIZE ESTIMATION 35
2.3.1 BOTTOM-UP APPROACH 35
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 35
2.3.2 TOP-DOWN APPROACH 35
FIGURE 5 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 35
2.4 SUPPLY-SIDE APPROACH 36
FIGURE 6 METHODOLOGY FOR SUPPLY-SIDE SIZING OF PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET (1/2) 36
FIGURE 7 METHODOLOGY FOR SUPPLY-SIDE SIZING OF PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET (2/2) 36
2.4.1 CALCULATIONS FOR SUPPLY-SIDE ANALYSIS 37
2.5 DATA TRIANGULATION 37
FIGURE 8 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: DATA TRIANGULATION 37
2.6 GROWTH FORECAST 38
2.7 GROWTH RATE ASSUMPTIONS 38
2.8 RESEARCH ASSUMPTIONS 38
2.9 RESEARCH LIMITATIONS 39
2.10 RISK ANALYSIS 39
2.11 IMPACT OF RECESSION 39
3 EXECUTIVE SUMMARY 40
TABLE 2 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET SNAPSHOT: 2023 VS. 2028 40
FIGURE 9 EXTENDED-RELEASE SEGMENT TO HOLD LARGER MARKET SHARE DURING FORECAST PERIOD 41
FIGURE 10 NORTH AMERICA TO LEAD THE PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET DURING FORECAST PERIOD 41
4 PREMIUM INSIGHTS 43
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET 43
FIGURE 11 RISE IN CASES OF MENTAL ILLNESS TO DRIVE MARKET 43
4.2 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY REGION 43
FIGURE 12 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 43
4.3 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION 44
FIGURE 13 EXTENDED-RELEASE SEGMENT TO GROW AT HIGHER CAGR DURING FORECAST PERIOD 44
4.4 NORTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET 44
FIGURE 14 EXTENDED-RELEASE APPLICATION ACCOUNTS FOR LARGER MARKET SHARE 44
5 MARKET OVERVIEW 45
5.1 INTRODUCTION 45
5.2 MARKET DYNAMICS 45
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET 45
5.2.1 DRIVERS 46
5.2.1.1 Rising cases of mental illness 46
FIGURE 16 PREVALENCE OF MENTAL DISORDERS ACROSS WHO REGIONS, 2019 46
5.2.1.1.1 Growing awareness of mental health 46
5.2.1.1.2 Changes in lifestyle and increase in stress 46
5.2.2 RESTRAINTS 47
5.2.2.1 Availability of substitutes 47
5.2.2.2 Side effects and safety concerns 47
5.2.3 OPPORTUNITIES 48
5.2.3.1 Potential for new applications owing to clinical research and innovation 48
5.2.4 CHALLENGES 48
5.2.4.1 Stringent pharmaceutical standards and regulations 48
5.2.4.2 Stigma and perception of mental disorders 48
6 INDUSTRY TRENDS 49
6.1 ECOSYSTEM MAPPING 49
FIGURE 17 ECOSYSTEM MAP OF PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET 49
TABLE 3 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: ECOSYSTEM MAPPING 50
6.2 VALUE CHAIN ANALYSIS 50
FIGURE 18 VALUE CHAIN ANALYSIS OF PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET 50
6.2.1 LITHIUM RESOURCE EXTRACTION AND PROCESSING 51
6.2.2 CONVERSION TO LITHIUM CARBONATE 51
6.2.3 PURIFICATION AND QUALITY CONTROL 51
6.2.4 PHARMACEUTICAL FORMULATION AND MANUFACTURING OF PHARMACEUTICAL PRODUCTS 51
6.2.5 REGULATORY COMPLIANCE AND TESTING 51
6.2.6 DISTRIBUTION AND SUPPLY CHAIN 51
6.2.7 PHARMACEUTICAL USE 51
6.3 TECHNOLOGY ANALYSIS 52
6.4 REGULATORY LANDSCAPE 53
6.4.1 REGULATIONS RELATED TO PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET 53
6.4.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 54
TABLE 4 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 54
TABLE 5 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 54
TABLE 6 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 55
TABLE 7 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 55
6.5 KEY CONFERENCES AND EVENTS, 2023–2024 56
TABLE 8 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: CONFERENCES AND EVENTS, 2023–2024 56
6.6 PATENT ANALYSIS 56
6.6.1 INTRODUCTION 56
6.6.2 METHODOLOGY 56
6.6.3 DOCUMENT TYPE 57
FIGURE 19 NUMBER OF GRANTED PATENTS, PATENT APPLICATIONS, AND LIMITED PATENTS 57
FIGURE 20 PUBLICATION TRENDS IN LAST 10 YEARS 57
6.6.4 INSIGHTS 58
FIGURE 21 LEGAL STATUS OF PATENTS 58
6.6.5 JURISDICTION ANALYSIS 58
FIGURE 22 TOP JURISDICTION, BY DOCUMENT 58
6.6.6 TOP COMPANIES/APPLICANTS 59
FIGURE 23 COMPANIES/APPLICANTS WITH HIGHEST NUMBER OF PATENTS 59
TABLE 9 PATENTS: OROCOBRE LIMITED 59
TABLE 10 PATENTS: CONTITECH USA INC. 59
TABLE 11 TOP PATENT OWNERS DURING LAST 10 YEARS 60
6.7 KEY STAKEHOLDERS AND BUYING CRITERIA 60
6.7.1 KEY STAKEHOLDERS IN BUYING PROCESS 60
FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP TWO APPLICATIONS 60
TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP TWO APPLICATIONS (%) 61
6.7.2 BUYING CRITERIA 61
FIGURE 25 KEY BUYING CRITERIA FOR TOP TWO APPLICATIONS 61
TABLE 13 KEY BUYING CRITERIA FOR TOP TWO APPLICATIONS 61
6.8 CASE STUDY ANALYSIS 62
6.8.1 OBJECTIVE 62
6.8.2 DESCRIPTION 62
6.8.3 METHOD 62
6.8.4 RESULTS 62
6.9 PORTER’S FIVE FORCES ANALYSIS 63
FIGURE 26 PORTER’S FIVE FORCES ANALYSIS OF PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET 63
TABLE 14 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: PORTER’S FIVE FORCES ANALYSIS 63
6.9.1 THREAT OF NEW ENTRANTS 64
6.9.2 THREAT OF SUBSTITUTES 64
6.9.3 BARGAINING POWER OF BUYERS 64
6.9.4 BARGAINING POWER OF SUPPLIERS 64
6.9.5 INTENSITY OF COMPETITIVE RIVALRY 65
6.10 TRADE ANALYSIS 65
6.10.1 IMPORT-EXPORT SCENARIO 65
TABLE 15 LITHIUM CARBONATE EXPORT TRADE DATA, 2022 65
TABLE 16 LITHIUM CARBONATE IMPORT TRADE DATA, 2022 65
6.11 PRICING ANALYSIS 66
6.11.1 AVERAGE SELLING PRICE FOR PHARMACEUTICAL GRADE LITHIUM CARBONATE, BY REGION IN 2022 66
FIGURE 27 AVERAGE SELLING PRICE, BY REGION 66
7 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY PURITY 67
7.1 INTRODUCTION 67
7.2 99.0% 67
7.3 ABOVE 99% 67
8 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION 68
8.1 INTRODUCTION 69
FIGURE 28 EXTENDED RELEASE TO BE LARGER MARKET SEGMENT DURING FORECAST PERIOD 69
TABLE 17 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (TON) 69
TABLE 18 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (TON) 69
TABLE 19 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (USD MILLION) 70
TABLE 20 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (USD MILLION) 70
8.2 IMMEDIATE RELEASE 70
8.2.1 IMMEDIATE-RELEASE MEDICINES PROVIDE RAPID RELIEF OF SYMPTOMS 70
TABLE 21 IMMEDIATE RELEASE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY REGION, 2019–2022 (TON) 70
TABLE 22 IMMEDIATE RELEASE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY REGION, 2023–2028 (TON) 71
TABLE 23 IMMEDIATE RELEASE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY REGION, 2019–2022 (USD MILLION) 71
TABLE 24 IMMEDIATE RELEASE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY REGION, 2023–2028 (USD MILLION) 71
8.3 EXTENDED RELEASE 72
8.3.1 EXTENDED-RELEASE MEDICINES REDUCE RISK OF SIDE EFFECTS 72
TABLE 25 EXTENDED RELEASE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY REGION, 2019–2022 (TON) 72
TABLE 26 EXTENDED RELEASE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY REGION, 2023–2028 (TON) 72
TABLE 27 EXTENDED RELEASE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY REGION, 2019–2022 (USD MILLION) 73
TABLE 28 EXTENDED RELEASE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY REGION, 2023–2028 (USD MILLION) 73
9 PHARMACEUTICAL GRADE LITHIUM CARBONATE, BY REGION 74
9.1 INTRODUCTION 75
FIGURE 29 NORTH AMERICA TO DRIVE PHARMACEUTICAL GRADE LITHIUM CARBONATE DURING FORECAST PERIOD 75
TABLE 29 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY REGION, 2019–2022 (USD MILLION) 75
TABLE 30 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY REGION, 2023–2028 (USD MILLION) 76
TABLE 31 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY REGION, 2019–2022 (TON) 76
TABLE 32 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY REGION, 2023–2028 (TON) 76
9.2 ASIA PACIFIC 77
9.2.1 RECESSION IMPACT 77
FIGURE 30 ASIA PACIFIC: PHARMACEUTICAL GRADE LITHIUM CARBONATE SNAPSHOT 78
TABLE 33 ASIA PACIFIC: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2019–2022 (USD MILLION) 78
TABLE 34 ASIA PACIFIC: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2023–2028 (USD MILLION) 79
TABLE 35 ASIA PACIFIC: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2019–2022 (TON) 79
TABLE 36 ASIA PACIFIC: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2023–2028 (TON) 79
TABLE 37 ASIA PACIFIC: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (USD MILLION) 80
TABLE 38 ASIA PACIFIC: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (USD MILLION) 80
TABLE 39 ASIA PACIFIC: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (TON) 80
TABLE 40 ASIA PACIFIC: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (TON) 80
9.2.2 CHINA 81
9.2.2.1 Expansion of treatment facilities pertaining to mental disorders to drive market 81
TABLE 41 CHINA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (USD MILLION) 81
TABLE 42 CHINA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (USD MILLION) 81
TABLE 43 CHINA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (TON) 81
TABLE 44 CHINA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (TON) 82
9.2.3 INDIA 82
9.2.3.1 Government initiatives for encouraging mental health treatments to drive demand 82
TABLE 45 INDIA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (USD MILLION) 82
TABLE 46 INDIA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (USD MILLION) 83
TABLE 47 INDIA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (TON) 83
TABLE 48 INDIA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (TON) 83
9.2.4 JAPAN 83
9.2.4.1 Increasing need for treatment of mental illnesses to drive market 83
TABLE 49 JAPAN: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (USD MILLION) 84
TABLE 50 JAPAN: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (USD MILLION) 84
TABLE 51 JAPAN: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (TON) 84
TABLE 52 JAPAN: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (TON) 84
9.2.5 SOUTH KOREA 85
9.2.5.1 Presence of mental health centers to improve research and increase demand 85
TABLE 53 SOUTH KOREA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (USD MILLION) 85
TABLE 54 SOUTH KOREA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (USD MILLION) 85
TABLE 55 SOUTH KOREA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (TON) 85
TABLE 56 SOUTH KOREA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (TON) 86
9.2.6 REST OF ASIA PACIFIC 86
TABLE 57 REST OF ASIA PACIFIC: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (USD MILLION) 86
TABLE 58 REST OF ASIA PACIFIC: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (USD MILLION) 86
TABLE 59 REST OF ASIA PACIFIC: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (TON) 87
TABLE 60 REST OF ASIA PACIFIC: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (TON) 87
9.3 NORTH AMERICA 87
9.3.1 RECESSION IMPACT 87
FIGURE 31 NORTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE SNAPSHOT 88
TABLE 61 NORTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2019–2022 (USD MILLION) 88
TABLE 62 NORTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2023–2028 (USD MILLION) 89
TABLE 63 NORTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2019–2022 (TON) 89
TABLE 64 NORTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2023–2028 (TON) 89
TABLE 65 NORTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (USD MILLION) 89
TABLE 66 NORTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (USD MILLION) 90
TABLE 67 NORTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (TON) 90
TABLE 68 NORTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (TON) 90
9.3.2 US 90
9.3.2.1 Laws pertaining to mental health and disorder treatment to drive demand 90
TABLE 69 US: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (USD MILLION) 91
TABLE 70 US: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (USD MILLION) 91
TABLE 71 US: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (TON) 91
TABLE 72 US: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (TON) 91
9.3.3 CANADA 92
9.3.3.1 Investment in quality mental health treatment to drive growth 92
TABLE 73 CANADA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (USD MILLION) 92
TABLE 74 CANADA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (USD MILLION) 92
TABLE 75 CANADA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (TON) 92
TABLE 76 CANADA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (TON) 93
9.3.4 MEXICO 93
9.3.4.1 Campaigns and educational initiatives to influence growth 93
TABLE 77 MEXICO: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (USD MILLION) 93
TABLE 78 MEXICO: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (USD MILLION) 93
TABLE 79 MEXICO: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (TON) 94
TABLE 80 MEXICO: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (TON) 94
9.4 EUROPE 94
9.4.1 RECESSION IMPACT 94
FIGURE 32 EUROPE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET SNAPSHOT 95
TABLE 81 EUROPE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2019–2022 (USD MILLION) 95
TABLE 82 EUROPE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2023–2028 (USD MILLION) 96
TABLE 83 EUROPE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2019–2022 (TON) 96
TABLE 84 EUROPE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2023–2028 (TON) 96
TABLE 85 EUROPE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (USD MILLION) 96
TABLE 86 EUROPE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (USD MILLION) 97
TABLE 87 EUROPE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (TON) 97
TABLE 88 EUROPE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (TON) 97
9.4.2 GERMANY 97
9.4.2.1 Well-established healthcare system to drive market 97
TABLE 89 GERMANY: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (USD MILLION) 98
TABLE 90 GERMANY: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (USD MILLION) 98
TABLE 91 GERMANY: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (TON) 98
TABLE 92 GERMANY: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (TON) 98
9.4.3 FRANCE 99
9.4.3.1 Support and initiative from government toward mental health issues to drive demand 99
TABLE 93 FRANCE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (USD MILLION) 99
TABLE 94 FRANCE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (USD MILLION) 99
TABLE 95 FRANCE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (TON) 99
TABLE 96 FRANCE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (TON) 100
9.4.4 UK 100
9.4.4.1 Growing cases of mental illness to drive demand 100
TABLE 97 UK: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (USD MILLION) 100
TABLE 98 UK: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (USD MILLION) 100
TABLE 99 UK: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (TON) 101
TABLE 100 UK: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (TON) 101
9.4.5 REST OF EUROPE 101
TABLE 101 REST OF EUROPE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (USD MILLION) 101
TABLE 102 REST OF EUROPE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (USD MILLION) 102
TABLE 103 REST OF EUROPE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (TON) 102
TABLE 104 REST OF EUROPE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (TON) 102
9.5 MIDDLE EAST & AFRICA 102
9.5.1 RECESSION IMPACT 102
TABLE 105 MIDDLE EAST & AFRICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2019–2022 (USD MILLION) 103
TABLE 106 MIDDLE EAST & AFRICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2023–2028 (USD MILLION) 103
TABLE 107 MIDDLE EAST & AFRICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2019–2022 (TON) 103
TABLE 108 MIDDLE EAST & AFRICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2023–2028 (TON) 103
TABLE 109 MIDDLE EAST & AFRICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (USD MILLION) 104
TABLE 110 MIDDLE EAST & AFRICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (USD MILLION) 104
TABLE 111 MIDDLE EAST & AFRICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (TON) 104
TABLE 112 MIDDLE EAST & AFRICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (TON) 104
9.5.2 SAUDI ARABIA 105
9.5.2.1 Growing awareness and government support for mental illness to drive demand 105
TABLE 113 SAUDI ARABIA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (USD MILLION) 105
TABLE 114 SAUDI ARABIA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (USD MILLION) 105
TABLE 115 SAUDI ARABIA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (TON) 105
TABLE 116 SAUDI ARABIA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (TON) 106
9.5.3 UAE 106
9.5.3.1 Growing investment to improve drug sector to drive demand 106
TABLE 117 UAE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (USD MILLION) 106
TABLE 118 UAE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (USD MILLION) 106
TABLE 119 UAE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (TON) 107
TABLE 120 UAE: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (TON) 107
9.5.3.2 Rest of Middle East & Africa 107
TABLE 121 REST OF MIDDLE EAST & AFRICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (USD MILLION) 107
TABLE 122 REST OF MIDDLE EAST & AFRICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (USD MILLION) 108
TABLE 123 REST OF MIDDLE EAST & AFRICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (TON) 108
TABLE 124 REST OF MIDDLE EAST & AFRICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (TON) 108
9.6 SOUTH AMERICA 108
9.6.1 RECESSION IMPACT 108
TABLE 125 SOUTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2019–2022 (USD MILLION) 109
TABLE 126 SOUTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2023–2028 (USD MILLION) 109
TABLE 127 SOUTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2019–2022 (TON) 109
TABLE 128 SOUTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY COUNTRY, 2023–2028 (TON) 109
TABLE 129 SOUTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (USD MILLION) 110
TABLE 130 SOUTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (USD MILLION) 110
TABLE 131 SOUTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (TON) 110
TABLE 132 SOUTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (TON) 110
9.6.2 BRAZIL 111
9.6.2.1 Growing efforts to raise awareness about mental health issues to drive market 111
TABLE 133 BRAZIL: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (USD MILLION) 111
TABLE 134 BRAZIL: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (USD MILLION) 111
TABLE 135 BRAZIL: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (TON) 111
TABLE 136 BRAZIL: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (TON) 112
9.6.3 REST OF SOUTH AMERICA 112
TABLE 137 REST OF SOUTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (USD MILLION) 112
TABLE 138 REST OF SOUTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (USD MILLION) 112
TABLE 139 REST OF SOUTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2019–2022 (TON) 112
TABLE 140 REST OF SOUTH AMERICA: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, BY APPLICATION, 2023–2028 (TON) 113
10 COMPETITIVE LANDSCAPE 114
10.1 INTRODUCTION 114
10.2 STRATEGIES ADOPTED BY KEY PLAYERS 114
TABLE 141 OVERVIEW OF STRATEGIES ADOPTED BY KEY MANUFACTURERS 114
10.3 MARKET SHARE ANALYSIS 115
10.3.1 RANKING OF KEY MARKET PLAYERS, 2022 115
FIGURE 33 RANKING OF KEY PLAYERS IN PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET, 2022 115
10.3.2 MARKET SHARE OF KEY PLAYERS 116
FIGURE 34 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET SHARE ANALYSIS 116
TABLE 142 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: DEGREE OF COMPETITION 116
10.3.2.1 Livent Corporation 117
10.3.2.2 Albemarle Corporation 117
10.3.2.3 Jiangsu Lianhuan Pharmaceutical Co., Ltd. 117
10.3.3 REVENUE ANALYSIS OF TOP PLAYERS 117
FIGURE 35 REVENUE ANALYSIS OF KEY COMPANIES, 2018–2022 117
10.4 COMPANY PRODUCT FOOTPRINT ANALYSIS 118
FIGURE 36 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: COMPANY FOOTPRINT 118
TABLE 143 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: PURITY FOOTPRINT 118
TABLE 144 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: COMPANY REGION FOOTPRINT 119
10.5 COMPANY EVALUATION MATRIX (TIER 1) 119
10.5.1 STARS 119
10.5.2 EMERGING LEADERS 119
10.5.3 PERVASIVE PLAYERS 119
10.5.4 PARTICIPANTS 120
FIGURE 37 COMPANY EVALUATION MATRIX: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET (TIER 1 COMPANIES) 120
10.6 COMPETITIVE BENCHMARKING 121
TABLE 145 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: KEY STARTUPS/SMES 121
TABLE 146 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 121
10.7 STARTUP/SME EVALUATION MATRIX 122
10.7.1 PROGRESSIVE COMPANIES 122
10.7.2 RESPONSIVE COMPANIES 122
10.7.3 DYNAMIC COMPANIES 122
10.7.4 STARTING BLOCKS 122
FIGURE 38 STARTUP/SME EVALUATION QUADRANT: PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET 123
10.8 COMPETITIVE SCENARIO 124
10.8.1 DEALS 124
TABLE 147 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: DEALS, 2019–2023 124
10.8.2 OTHER DEVELOPMENTS 124
TABLE 148 PHARMACEUTICAL GRADE LITHIUM CARBONATE MARKET: EXPANSIONS AND INVESTMENTS, 2019–2023 124
11 COMPANY PROFILES 125
(Business overview, Products/Solutions/Services offered, Recent Developments, MNM view)*
11.1 MAJOR PLAYERS 125
11.1.1 LIVENT CORPORATION 125
TABLE 149 LIVENT CORPORATION: COMPANY OVERVIEW 125
FIGURE 39 LIVENT CORPORATION: COMPANY SNAPSHOT 126
TABLE 150 LIVENT CORPORATION: PRODUCTS OFFERED 126
TABLE 151 LIVENT CORPORATION: DEALS 127
11.1.2 ALBEMARLE CORPORATION 129
TABLE 152 ALBEMARLE CORPORATION: COMPANY OVERVIEW 129
FIGURE 40 ALBEMARLE CORPORATION: COMPANY SNAPSHOT 130
TABLE 153 ALBEMARLE CORPORATION: PRODUCTS OFFERED 130
TABLE 154 ALBEMARLE CORPORATION: OTHERS 131
11.1.3 JIANGSU LIANHUAN PHARMACEUTICAL CO., LTD. 132
TABLE 155 JIANGSU LIANHUAN PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW 132
FIGURE 41 JIANGSU LIANHUAN PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT 133
TABLE 156 JIANGSU LIANHUAN PHARMACEUTICAL CO., LTD.: PRODUCTS OFFERED 133
11.1.4 AMERICAN ELEMENTS 135
TABLE 157 AMERICAN ELEMENTS: COMPANY OVERVIEW 135
TABLE 158 AMERICAN ELEMENTS: PRODUCTS OFFERED 135
11.1.5 GLOBE QUÍMICA 136
TABLE 159 GLOBE QUÍMICA: COMPANY OVERVIEW 136
TABLE 160 GLOBE QUÍMICA: PRODUCTS OFFERED 136
11.1.6 JIANGSU NHWA PHARMACEUTICAL CO., LTD. 137
TABLE 161 JIANGSU NHWA PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW 137
TABLE 162 JIANGSU NHWA PHARMACEUTICAL CO., LTD.: PRODUCTS OFFERED 137
11.1.7 PANCHSHEEL ORGANICS LTD (POLTD) 138
TABLE 163 PANCHSHEEL ORGANICS LTD (POLTD): COMPANY OVERVIEW 138
FIGURE 42 PANCHSHEEL ORGANICS LTD (POLTD): COMPANY SNAPSHOT 138
TABLE 164 PANCHSHEEL ORGANICS LTD (POLTD): PRODUCTS OFFERED 139
11.1.8 BLANVER 140
TABLE 165 BLANVER: COMPANY OVERVIEW 140
TABLE 166 BLANVER: PRODUCTS OFFERED 140
11.2 OTHER PLAYERS 141
11.2.1 ZHENJIANG POWORKS CO., LTD. 141
TABLE 167 ZHENJIANG POWORKS CO., LTD.: COMPANY OVERVIEW 141
11.2.2 AXIOM CHEMICALS PVT. LTD. 142
TABLE 168 AXIOM CHEMICALS PVT. LTD.: COMPANY OVERVIEW 142
11.2.3 HUBEI RISON CHEMICAL CO., LTD. 143
TABLE 169 HUBEI RISON CHEMICAL CO., LTD.: COMPANY OVERVIEW 143
11.2.4 PHARMAFFILIATES ANALYTICS AND SYNTHETICS P. LTD. 144
TABLE 170 PHARMAFFILIATES ANALYTICS AND SYNTHETICS P. LTD.: COMPANY OVERVIEW 144
*Details on Business overview, Products/Solutions/Services offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
12 APPENDIX 145
12.1 DISCUSSION GUIDE 145
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 147
12.3 CUSTOMIZATION OPTIONS 149
12.4 RELATED REPORTS 149
12.5 AUTHOR DETAILS 150
世界の医薬品用炭酸リチウム市場（～2028年）：用途別（徐放、即時放出）、純度別（99%、99%以上）、地域別（アジア太平洋、ヨーロッパ、北米、中東・アフリカ、南米） |
| 【英語タイトル】Pharmaceutical Grade Lithium Carbonate Market by Application (Extended Release, Immediate Release), Purity (99%, Above 99%), and Region (Asia Pacific, Europe, North America, Middle East & Africa, and South America) - Global Forecast to 2028 | |
 | ・商品コード：MM8781-23 ・発行会社（調査会社）：MarketsandMarkets ・発行日：2023年9月30日 ・ページ数：144 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（受注後24時間以内） ・調査対象地域：グローバル ・産業分野：医薬品 |
| Single User（1名様閲覧） | USD4,950 ⇒換算￥752,400 | 見積依頼/購入/質問フォーム |
| Multi User (Five User) | USD6,650 ⇒換算￥1,010,800 | 見積依頼/購入/質問フォーム |
| Corporate License (全社内共有可) | USD8,150 ⇒換算￥1,238,800 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| "医薬品用炭酸リチウム市場は、2023年の141百万米ドルから2028年には166百万米ドルに成長し、2023年から2028年までの年平均成長率は3.3％と予測" 炭酸リチウムは、双極性障害などの精神疾患の治療における気分安定剤として一般的に使用されています。メンタルヘルスに対する意識が高まり、治療を求める人が増えるにつれて、医薬品用炭酸リチウムの需要は増加する見込みです。 "用途別では、2023年から2028年にかけて徐放性セグメントがより大きなセグメントになる見込み" 医薬品用炭酸リチウムは、長期間にわたって徐々に薬物を放出します。これにより、血流中の薬物濃度がより安定し、即時放出型薬剤で起こりうる変動が減少します。このように体内の薬物濃度が安定することで、治療成績が向上し、副作用が軽減されます。また、不安やその他の精神疾患に苦しむ患者の多くは、長期的な治療を必要とします。徐放性製剤は、長期間にわたって効果が持続するため、頻繁な投与の必要性を減らし、患者のQOLを向上させることができるため、これらの疾患には特に有益です。 "地域別では、2023年に北米が金額ベースで最大の市場になる見込み" 北米ではメンタルヘルスに対する意識が高まっており、双極性障害のような疾患の認知・診断が進んでいます。炭酸リチウムは双極性障害の一般的な治療薬であり、治療を求める人が増えるにつれて、医薬品用炭酸リチウムの需要が増加する見込みです。北米は医療インフラが発達しており、医薬品の効果的な流通と入手が可能です。医薬品用炭酸リチウムを含む医療サービスと医薬品が入手可能であることが、市場の成長に寄与しています。 主な参入企業のプロフィールは以下の通りです： - 企業タイプ別：ティア1：65％、ティア2：20％、ティア3：15％ - 役職別 Cレベル幹部：25％、取締役：30％、その他：45％ - 地域別 北米：20％、ヨーロッパ：15％、アジア太平洋：55％、中東・アフリカ：3％、南米：7％ 医薬品用炭酸リチウムレポートは、Livent Corporation (US), Albemarle Corporation (US), Jiangsu Lianhuan Pharmaceutical Co., Ltd. (China), American Elements (US), Globe Química (US), Jiangsu Nhwa Pharmaceutical Co., Ltd. (China), Panchsheel Organics Ltd (POLTD) (India), Blanver (Brazil)などの主要企業が含まれます。 調査範囲： この調査レポートは、医薬品用炭酸リチウム市場を用途、純度、地域別に定義、セグメント化し、市場規模を予測しています。主要企業を戦略的にプロファイルし、市場シェアとコアコンピタンスを包括的に分析を行っています。また、製品発売、契約、買収、市場での投資など、競合他社の動向も追跡・分析しています。 レポート購入の理由： 本レポートは、医薬品用炭酸リチウム市場とそのセグメントの収益数の最も近い近似値を提供することにより、市場のリーダー/新規参入者を支援することが期待されます。当レポートはまた、利害関係者が市場の競争状況について理解を深め、事業の地位を向上させ、適切な市場参入戦略を立てるための洞察を得るのに役立つものと期待されます。また、利害関係者が市場の鼓動を理解し、主要な市場促進要因、阻害要因、課題、機会に関する情報を提供することも可能にします。 本レポートは、以下のポイントに関する洞察を提供します： - 医薬品用炭酸リチウム市場の成長に影響を与える主要な促進要因（精神疾患の症例の増加）、阻害要因（副作用と安全性の懸念）、機会（臨床研究と技術革新による新たな用途の可能性）、課題（精神疾患に対する偏見と認識）の分析を行っています。 - 製品開発/イノベーション：医薬品グレード炭酸リチウム市場における今後の技術、研究開発活動に関する詳細な洞察を掲載しています。 - 市場開発：有利な市場に関する包括的な情報-当レポートでは、様々な地域の医薬品グレード炭酸リチウム市場を分析しています。 - 市場の多様化：医薬品用炭酸リチウム市場における新製品、様々な生産技術、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。 - 競合他社の評価：Livent Corporation (US), Albemarle Corporation (US), Jiangsu Lianhuan Pharmaceutical Co., Ltd. (China), American Elements (US), Globe Química (US), Jiangsu Nhwa Pharmaceutical Co., Ltd. (China), Panchsheel Organics Ltd (POLTD) (India), Blanver (Brazil)など主要企業の市場シェア、成長戦略、製品展開などを詳細に評価しています。 |
1.イントロダクション
2.調査方法
3.エグゼクティブサマリー
4.プレミアムインサイト
5.市場概要
6.産業動向
7.医薬品用炭酸リチウムの市場分析：純度別
8.医薬品用炭酸リチウムの市場分析：用途別
9.医薬品用炭酸リチウムの市場分析：地域別
10.競争状況
11.企業情報
12.付録
❖ レポートの目次 ❖
| ★調査レポート[世界の医薬品用炭酸リチウム市場（～2028年）：用途別（徐放、即時放出）、純度別（99%、99%以上）、地域別（アジア太平洋、ヨーロッパ、北米、中東・アフリカ、南米）] (コード：MM8781-23)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界の医薬品用炭酸リチウム市場（～2028年）：用途別（徐放、即時放出）、純度別（99%、99%以上）、地域別（アジア太平洋、ヨーロッパ、北米、中東・アフリカ、南米）]についてメールでお問い合わせ |
